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ABSTRACT 
Neuroblastoma, the most common extra-cranial childhood tumour, is believed to arise from 
precursor cells of the sympathetic nervous system (neuroblasts). Hemizygous loss of 
chromosome 1p36 strongly correlates with poor prognosis in neuroblastoma and the 1p36 
gene KIF1Bβ has been proposed to be a pathogenic target of this deletion. KIF1Bβ is 
required for normal developmental apoptosis of neuroblasts induced by competition for NGF 
during embryogenesis. We hypothesised that KIF1Bβ’s role in developmental culling of 
neuroblasts is a molecular mechanism that suppresses neuroblastoma development. 
In Paper I, we found that KIF1Bβ causes apoptosis through interaction with RNA helicase A 
(DHX9), promoting accumulation of DHX9 in the nucleus, and up-regulation of proapoptotic 
XIAP-associated factor 1 (XAF1). We demonstrate that NGF deprivation induced apoptosis 
requires DHX9 and that loss of KIF1Bβ expression in neuroblastomas with hemizygous 
deletion of 1p36 impairs DHX9 nuclear localization, implicating loss of DHX9 nuclear 
activity in neuroblastoma pathogenesis. 
In Paper II,  we discovered that the Ca2+-dependent phosphatase calcineurin (CN) is 
activated by KIF1Bβ. CN mediates a diversity of cellular responses, and its activity is 
affected in various diseases. We show that KIF1Bβ effects mitochondrial dynamics through 
dephosphorylation of Dynamin-related protein 1 (DRP1) by CN, causing mitochondrial 
fission and apoptosis. We found that KIF1Bβ enables CN recognition of all known substrates, 
and DHX9, suggesting a general involvement of KIF1Bβ in CN signalling activity. DRP1 
dephosphorylation or CN activity could not be stimulated by pathogenic KIF1Bβ mutations 
previously identified in neuroblastomas and ,0pheochromocytomas. Loss of KIF1Bβ and 
DRP1 expression in 1p36 hemizygous-deleted neuroblastomas, implies that dysregulation of 
mitochondrial dynamics and calcineurin activity affect high-risk and poor-prognosis 
neuroblastoma. 
In Paper III, we showed that loss of KIF1Bβ in the sympathetic nervous system impairs 
nervous development and function and dysregulates genes required for sympathoadrenal 
lineage differentiation. We discovered that KIF1Bβ mediates anterograde transport of the 
NGF receptor TRKA and is required for NGF-dependent neuronal differentiation.  Moreover, 
TRKA transport is impeded by pathogenic KIF1Bβ mutations identified in neuroblastoma. 
We observed reduced expression of neuronal differentiation proteins in KIF1Bβ deficient 
mouse neuroblasts and primary human neuroblastomas that lack KIF1Bβ. Furthermore, 
transcriptomic analyses revealed that loss of KIF1Bβ in mouse sympathetic neuroblasts 
causes changes in gene expression similar to those seen in high-risk neuroblastoma, 
independent of MYCN amplification and the loss of genes neighbouring KIF1B on 
chromosome 1p36. 
Thus, defective precursor cell differentiation, and impaired apoptosis, common traits of 
aggressive childhood malignancies, are pathogenic effects of KIF1Bβ loss in neuroblastoma. 
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1 INTRODUCTION 
 
1.1 WHAT IS CANCER? 
 
Cancer is essentially the unusual and injurious growth of cells that have the ability to spread 
to and grow in other parts of the body. It is not one disease as such, but the result of cells 
gaining the capacity to grow when and or where they wouldn’t normally, and then invading 
other parts of the body and growing there. Viral infections, exposure to certain substances, 
hormonal imbalances, stress, exposure to radiation and even old age can cause cancer. The 
factors are diverse, but they have something in common. They all act on our genes or the way 
our genes are expressed. Correct expression of our genes is essential for maintaining the 
normal identity of a cell, e.g. as a blood cell, muscle cell or neuron. 
 
1.2 MUTATIONS! 
 
Genetic (or genomic) instability is an essential feature of cancer, because it allows cells to 
transform into something else. Cancer cells must be able to survive, proliferate and spread 
outside their original environment. Genomic instability, involving mutations and changes in 
gene expression, creates a permissive environment for the acquisition of new cellular 
characteristics, and subsequent selection for traits that are advantageous for fledgling cancer 
cells.  
Cancer is predominantly a disease of the elderly, and this is most probably due to 
accumulation of genetic damage over time. In a large metastudy of cancer associated 
mutations, Vogelstein and colleagues found that tumours that tend to develop during adult 
life, such as brain, colon, pancreas or breast cancers, harbour function affecting somatic 
mutations in between 33 to 66 genes on average (Vogelstein et al., 2013). This number rises 
to around 200 genes with predicted functional mutations in cancers where a strong mutagen 
(ie UV light or cigarette smoke) is a driving oncogenic factor, such as in melanoma and lung 
cancer.  
 
1.3 CHILDHOOD VS ADULT CANCER  
 
The mutational status of paediatric malignancies, contrasts strongly with that observed in 
adult cancer. Relatively few function-affecting somatic mutations occur in childhood cancers 
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(Alexandrov et al., 2013; Vogelstein et al., 2013) For example, Vogelstein and colleagues 
report only 9.6 point mutations on average in paediatric leukaemia and solid tumours 
(Vogelstein et al., 2013), and similar numbers have been reported in neuroblastoma 
(Molenaar et al., 2012) and medulloblastoma (Parsons et al., 2008). Over time, cells 
accumulate mutations and it is logical to expect that as the number of mutations increases so 
too does the probability that some of the mutations attained will have the capacity to drive 
cancer development (Beerenwinkel et al., 2007). How then does it take many years, and 10s-
100s of protein-changing mutations for a full-blown metastatic colorectal cancer to take hold, 
while a paediatric cancer with only a handful of amino acid effecting mutations may reach 
metastasis in a 1 year old child? One potential explanation for this would be that childhood 
cancers are primarily driven by inherited mutations. However, the presence of predisposing 
germ line genetic lesions in childhood cancers is generally quite low. Previous studies have 
estimated that hereditary disease accounts for less than 5% of neuroblastoma (Maris et al., 
2002), and around 8.5% of all paediatric cancers (Zhang et al., 2015). Although the actual 
figures are likely to be higher due to the relatively poor biological understanding of paediatric 
cancers compared to adult cancer. Nevertheless, hereditary disease is believed to contribute to 
around 10% of adult cancer cases, suggesting that germ line mutations do not make a special 
contribution to childhood cancer evolution, however this figure is likely affected by the 
effects of treatment on the future fertility of childhood cancer survivors (Wallace et al., 
2005). 
 
1.4 WHY DO PAEDIATRIC CANCERS HARBOUR FEWER MUTATIONS? 
 
Cancer is a heterogeneous disease. Although a tumour may develop from one single, 
cancerous cell of origin, tumours are most often complex and contain not just a variety of 
different tumour cells, but also a range of other recruited cell types that contribute to the 
structure and ecology within the tumour. Importantly, this diversity is often a factor in disease 
progression and the failure of treatment (Hanahan and Weinberg, 2011). The structural 
organisation within tumours can resemble that seen in normal tissues, where a small minority 
of cells are responsible for tumour growth (Kreso and Dick, 2014). The cancer stem cell 
hypothesis (Valent et al., 2012) was born out of this realisation that a small fraction of cells 
within a tumour resemble embryonic stem cells or have the ability to revert to an embryonic 
character.  While these ‘cancer stem cells’ are not identical with their embryonic 
counterparts, it is clear that they have either retained or regained embryonic features that 
confer a selective advantage at some stage during tumour development.  
Is it possible that it typically takes decades for cancer to develop in certain tissues because the 
number and type of mutations required to ‘unlock’ the embryonic potential of fully 
differentiated cells is quite high? On the other hand, cancers that become apparent in young 
children must have developed quite rapidly. Is this quick evolution a consequence of the 
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relatively minor transformation required to turn immature or embryonal cells into cancer 
cells? Or are already mature cells more susceptible to reversion to an embryonic state in a 
conducive pre and postnatal environment?  There is evidence to suggest that many childhood 
tumours have a prenatal cell of origin. However, it is not clear if there is a unifying model for 
paediatric oncogenesis, i.e. that  one or two oncogenic events affecting key genes can drive 
rapid tumour development, as proposed for paediatric leukaemia and malignant rhabdoid 
tumours (Biegel et al., 1999; Schmiegelow et al., 2008; Versteege et al., 1998)  or whether a 
diversity of tissue and cell type dependent mechanisms contribute to oncogenesis. Certainly, 
the low number of mutations associated with childhood malignancies suggests that only a few 
genetic hits are required to drive paediatric oncogenesis. 
 
1.5 THE ‘REST CELL’ HYPOTHESIS 
 
The concept of a cancer stem cell is not new. It is rather a reformulation of an old concept 
first communicated in the 19th century (summarised in Marshall et al., 2014; Ratajczak et al., 
2009). The rest cell hypothesis proposes that tumours arise from embryonic remnant or ‘rest’ 
cells that lay dormant in tissues after normal development, but can be reactivated and become 
cancerous. This scenario is particularly easy to conceive when excess cells are produced 
during embryogenesis, and mechanisms are required to remove these extra cells during tissue 
and organ formation. A good example of this is in the peripheral nervous system where 
terminally differentiating neurons compete for limited amounts of trophic factor upon which 
they are dependent. Evasion of normal cell death by such a mechanism might be the first step 
in a cell’s journey towards forming a tumour. 
The rest cell hypothesis is particularly interesting in relation to childhood cancers, where 
tumour progression occurs quickly and early in the child’s life. The early onset of some 
malignancies suggests that the first oncogenic events take place during the prenatal period, or, 
at the latest, not long after birth. Indeed, evidence is beginning to point towards an embryonic 
cell of origin for several paediatric cancers. Amongst the leukaemias, B-cell lineage acute 
lymphoblastic leukaemia and myeloid leukaemia- down syndrome both appear to have an 
embryonic origin, as the diseases present already in newborns (Gruhn et al., 2008; Pine et al., 
2007). There is also evidence that the nervous system tumours medulloblastoma and 
neuroblastoma have an embryonic origin. Together, these four cancers account for around 
40% of paediatric cancer cases (Downing et al., 2012) implying that many, if not most, 
paediatric cancers probably begin in the foetus. 
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1.6 NEUROBLASTOMA 
 
Neuroblastoma is the most commonly occurring childhood tumour outside of the brain and is 
the most common cancer diagnosed during the first year of life (Maris, 2010). Although 
neuroblastoma accounts for about 5-10% of all paediatric cancers (Jiang et al., 2011; Zhang 
et al., 2015), it is responsible for a disproportionately high number (around 15%) of 
childhood-cancer related deaths in patients younger than 15 years (Maris et al., 2007). At the 
time of diagnosis, the disease has most often already reached an advanced, metastatic state, 
leading to poor clinical outcomes. It arises in the sympathetic nervous system, most 
commonly in or around the adrenal glands and along the paravertebral ganglia. 
Neuroblastoma presents as a very variable disease ranging from a large benign primary mass 
to highly infiltrative and metastatic disease with fatal secondary effects. A particular subtype 
of neuroblastoma  (4s) is often first discovered at a highly metastatic state only to 
spontaneously regress without any clinical intervention (Maris et al., 2007). 
The heterogeneity of neuroblastoma, both biologically and in clinical presentation and 
response to treatment, leads to frequent failure of therapy, with survival rates of only 30% in 
high risk patients (Cohn et al., 2009). At the same time, neuroblastoma has one of the highest 
reported rates of spontaneous regression of all human cancers (Carlsen, 1990; Yamamoto et 
al., 1998). Despite significant efforts to investigate the molecular mechanisms that promote 
neuroblastoma development, the disease still presents a clinical challenge. A better 
understanding of the molecular pathogenesis behind the disease is required to improve 
treatment strategies and identify potential new chemotherapeutic targets. In particular, 
increased understanding of the role of cancer stem cells and the developmental biology of the 
sympathetic nervous system, both of the molecular biochemistry and the types of processes at 
play should be particularly helpful in understanding and treating neuroblastoma, and perhaps 
embryonal tumours in general. 
 
1.7 NEUROBLASTOMA CELL OF ORIGIN 
 
Neuroblastoma is believed to arise from sympathetic neuron progenitor cells, neuroblasts. 
The sympathetic nervous system is part of the autonomic nervous system that coordinates the 
body’s unconscious actions. The main function of the sympathetic nervous system (SNS) is 
to control the ‘flight-or-fight’ response, through the release of noradrenalin to peripheral 
target tissues. However, the SNS also helps to maintain homeostasis through basic levels of 
activity. As examples, nipple erection, sweating, ejaculation, respiration and pupil dilation are 
all subject to sympathetic control. The sympathetic nervous system is composed of 
preganglionic neurons, situated in the spinal cord, and their synaptic targets, postganglionic 
sympathetic neurons that innervate a diverse range of peripheral targets. The cell bodies of 
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postganglionic sympathetic neurons reside in ganglia that are found in a paravertebral chain, 
along with the celiac and mesenteric ganglia and the adrenal medulla (Purves, 2012).The 
majority of neuroblastomas arise in the adrenal medulla, although they can appear anywhere 
along the sympathetic chain (Maris, 2010). Gene expression studies have shown that 
neuroblastoma tumour cells resemble the neuroblast cells present during embryonic 
development of the SNS (De Preter et al., 2006). 
 
1.8 NEUROBLASTS AND SYMPATHETIC NEURON DEVELOPMENT 
 
Sympathetic neurons originate from migratory neural crest cells, known as neuroblasts, that 
assemble in the vicinity of the dorsal aorta at around embryonic day 10.5 in mice (Figure 
1A). Bone Morphogenetic proteins secreted from the dorsal aorta prompt adjacent 
parenchymal cells to produce stromal derived factor 1 (SDF1) and Neuregulin 1 (NRG1) 
(Saito et al., 2012; Schneider et al., 1999) that, in turn, stimulate the expression of PHOX2B 
and MASH1 in neuroblasts. PHOX2B and MASH1 initiate the expression of genes required 
for sympathetic neuron differentiation and later noradrenergic function, such as PHOX2A, 
HAND2, GATA3, TH, DBH, STMN2 and NEFH (Guillemot et al., 1993; Jiang et al., 2011; 
Pattyn et al., 1999). 
Interestingly, and in contrast to the classical models of neurogenesis and differentiation in the 
central nervous system, sympathetic neuron differentiation does not follow terminal cell cycle 
exit. Sympathetic neuroblasts already expressing the aforementioned neuronal and 
noradrenergic proteins undergo a wave of proliferation between E11.5 and E15.5 (Gonsalvez 
et al., 2013), before they start to extend axons and terminally differentiate. This expansion of 
the neuroblast population corresponds with transient expression of ALK (Vernersson et al., 
2006), and implicitly, MYCN (Edsjö et al., 2004; Umapathy et al., 2014; Wakamatsu et al., 
1997). Both genes are strongly linked to neuroblastoma,  suggesting that this peculiar 
proliferative behaviour of sympathetic neuroblasts may have a role in neuroblastoma 
pathogenesis, and could potentially explain why neuroblastoma does not arise in other parts 
of the nervous system. 
Segregation of the primordial sympathetic chain into distinct ganglia occurs simultaneously 
(from around embryonic day 11.5-12 for the cervical sympathetic ganglia in mice) and 
depends upon local secretion of GDNF family ligands (GFLs) by surrounding tissue and 
subsequent stimulation of the RET tyrosine kinase in sympathetic neuron precursors 
(Enomoto et al., 2001; Honma et al., 2002; Nishino et al., 1999) (Figure 1B).  
Local secretion of ligands from several groups of trophic factors stimulates axon extension, 
guidance and eventual connection of sympathetic neurons with peripheral targets (Glebova 
and Ginty, 2005). GFL-RET signalling is also required for initial axon extension, through the 
actions of the ligand ARTN, on GFRA3 and RET (Enomoto et al., 2001; Honma et al., 2002; 
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Nishino et al., 1999) (Figure 1B). The neurotrophin NTF3 is also required for initial axon 
extension, however some evidence suggests that it does not act through it’s high-affinity 
receptor, TRKC, but rather through the related neurotrophin receptor, TRKA (Kuruvilla et al., 
2004; Wyatt, 1997). Sympathetic axons extend primarily along arterial vasculature and other 
signalling factors secreted along the vasculature, both known and unknown, are also required 
for axonal guidance of specific neuronal subtypes (Glebova and Ginty, 2005; Honma et al., 
2002; Makita et al., 2008).  
On the other hand, distal axon extension and target innervation occur in response to nerve 
growth factor (NGF) released by sympathetic target tissues ((Crowley et al., 1994; Fagan et 
al., 1996; Glebova, 2004). NGF binding to the receptor tyrosine kinase TRKA stimulates a 
potent, dependence inducing, neurotrophic signalling program that culminates in nascent 
sympathetic neurons competing for NGF during synaptogenesis (Chao and Ip, 2010; Glebova 
and Ginty, 2005). 
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Figure 1: (A) General schema of sympathetic neuroblast mirgation and development with (B) timing of impor-
tant developmental events and gene expression. Gray arows and proteins indicate the action of locally secreted 
factors on neuroblast development
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1.9 DEVELOPMENTAL CULLING OF EXCESS NEURONS 
 
An excess of sympathetic neuroblasts are produced during embryogenesis and these are 
removed by programmed cell death during the late prenatal and early postnatal period. 
Culling of excess neurons occurs via competition for growth factors, such as NGF. The 
mature peripheral nervous system is essentially sculpted from an embryonic block via this 
process that kills up to 50% of neuronal precursors. 
Over 60 years ago, classic experiments by Levi-Montalcini and Booker revealed that NGF 
has a critical role in determining the number of neurons in the sympathetic nervous system 
(Levi-Montalcini and Booker, 1960a, 1960b). NGF secreted by target organs binds TRKA on 
the surface of nearby sympathetic axons. The amount of NGF secreted by target tissues is 
important for determining the number of neurons by which they are innervated. Secretion of 
less NGF allows for the survival of fewer neurons due to increased apoptosis, and subsequent 
in vivo studies in mice have verified that genetic deletion of NGF or TRKA reduces the 
number of sympathetic neurons via increased apoptosis during development (Brennan et al., 
1999; Crowley et al., 1994; Fagan et al., 1996). 
Developing sympathetic neurons in the mouse superior cervical ganglion (SCG) become 
dependent on the trophic stimulus provided by NGF binding to TRKA from around 
embryonic day 15 (E15)  (Crowley et al., 1994; Fagan et al., 1996). SCG neurons begin to die 
via apoptosis from around E17 as the amount of NGF available becomes limiting and they 
effectively ‘compete’ for NGF. Neurons that are deprived of NGF relative to their 
competitors die (Deppmann et al., 2008). This NGF deprivation induced apoptosis can be 
simulated in vitro with primary cultures of sympathetic neurons and has been well studied as 
a model for neuronal apoptosis. 
The molecular mechanisms behind developmental apoptosis of sympathetic neurons have 
been studied in vitro for over 20 years. It is well established that withdrawal of NGF activates 
the mitochondrial pathway of apoptosis and that kinase signalling through the JNK-JUN 
pathway and de novo gene expression are required (Kristiansen and Ham, 2014). 
Interestingly, this apoptotic pathway is also dependent on oxygen sensing mechanisms. 
Removal of the oxygen sensing prolyl-hydroxylase EGLN3 in mice results in enlarged 
sympathetic ganglia due to impaired developmental culling of neurons and this effect is at 
least partially mitigated by concurrent removal of one allele of the hypoxia inducible 
transcription factor EPAS1 (Bishop et al., 2008). Yet the precise mechanisms causing these 
effects on neuronal apoptosis remain elusive. 
Despite the large number of studies published on this topic much is still unknown, or a matter 
of debate. For example, a recent study suggested that TRKA can act as a dependence receptor 
that causes sympathetic neuron cell death in the absence of NGF (Nikoletopoulou et al., 
2010). However, the molecular mechanisms that would explain this activity are yet to be 
described. Other studies have indicated the involvement of P75NTR and other neurotrophins, 
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BDNF and NTF3, in NGF deprivation induced apoptosis (Bamji et al., 1998; Brennan et al., 
1999; Kenchappa et al., 2006), and provide reasonably compelling data. Yet, generally many 
findings in this field generated from in vitro data are not clearly reflected in vivo, and 
different research groups have drawn contrasting conclusions from the same genetic 
knockouts (Bamji et al., 1998; Brennan et al., 1999; Ernfors et al., 1994, 1995). Undoubtedly, 
the in vitro model of apoptosis caused by NGF deprivation is and has been a valuable tool for 
investigating the molecular mechanisms at play during developmental culling of sympathetic 
neurons. Unfortunately, our ability to draw relevant conclusions from this model is 
complicated by its relationship to the inherently greater complexity of the developmental 
processes and molecular mechanisms at play in the in vivo environment occupied by 
sympathetic neurons during development.  
Pheochromocytoma is a cancer related to neuroblastoma that originates in chromaffin cells 
also derived from the sympathoadrenal cell lineage. Prior studies have suggested that 
germline mutations in HRAS, RET, VHL, SDHD and KIF1B predispose to 
pheochromocytoma, and a related tumour, paraganglioma, by impeding developmental 
apoptosis after NGF withdrawal (Dahia, 2014; Lee et al., 2005; Yeh et al., 2008). Reduced 
neuronal culling and subsequent retention of excess progenitor cells might set a platform for 
later tumour development. Presumably, these remnant embryonic cells might have, or 
acquire, the ability to later form pheochromocytoma, or other related tumours, a la the rest 
cell hypothesis. Such a conserved mechanism of familiar predisposition through defects in 
embryonic development could also help explain the relatively high penetrance of heritable 
paraganglioma and pheochromocytoma (Dahia, 2014). Similarly, several candidate 
neuroblastoma tumour suppressors and oncogenes are also linked to developmental 
apoptosis. 
 
1.10 COMMON GENETIC FEATURES OF NEUROBLASTOMA 
 
As in other paediatric cancers, only few recurrent gene-specific mutations have been 
associated with neuroblastoma and this has led to difficulties in developing targeted treatment 
strategies for this disease. The most commonly detected gene alterations are amplification of 
MYCN and activating mutations of ALK, that occur in around 20% and 7% of cases 
respectively (Molenaar et al., 2012). Instead, oncogenic alteration of DNA in neuroblastoma 
is dominated by larger chromosomal rearrangements. Loss of chromosomal regions at 1p36 
(25-35% of cases) and 11q23 (35-45%) and gain of 17q22 (around 50%) are more prevalent, 
and are associated with unfavourable prognosis (reviewed in Jiang et al., 2011). 
Loss-of-heterozygosity at 1p36 is common in neuroblastoma (Maris et al., 2000; Martinsson 
et al., 1995) and numerous studies have proposed CAMTA1, CASZ1, CHD5, TP73, 
MIR34A and KIF1Bβ respectively as 1p36-encoded tumour suppressors (Egan et al., 2013; 
Henrich et al., 2011; Ichimiya et al., 1999; Liu et al., 2011; Munirajan et al., 2008; Schlisio et 
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al., 2008; Thompson et al., 2003; Welch et al., 2007). While no bona fide tumour suppressor 
function has yet been ascribed to any of the these genes individually, the collective loss of 
these genes that occurs with 1p36 deletion is likely to have a potent tumorigenic effect on the 
precursor cells of the sympathetic nervous system, from which neuroblastoma is believed to 
arise. 
 
1.11 KIF1BΒ, A CANDIDATE 1P36 TUMOUR SUPPRESSOR PROTEIN 
 
The first suggestion that KIF1Bβ might act as a 1p36 tumour suppressor protein came from 
the report of a neuroblastoma cell line (NB1) with a small 500-kb homozygous deletion at 
1p36.2 that harboured at least six genes (Nagai et al., 2000). Of these genes, only KIF1Bβ 
demonstrated tumour suppressor activity and had altered expression in neuroblastomas. 
Further in vitro studies have demonstrated that KIF1Bβ is critical for apoptosis in 
sympathetic neuron progenitors in response to NGF deprivation. In a study investigating the 
role of oxygen-sensing and EGLN3 in neuronal culling, Schlisio and colleagues used a 
genome-wide RNAi screen to discover that KIF1Bβ acts downstream of EGLN3 to induce 
apoptosis (Schlisio et al., 2008). They showed that KIF1Bβ is both necessary and sufficient 
for NGF deprivation induced apoptosis, and that several inherited missense mutations of 
KIF1Bβ in neuroblastoma and pheochromocytoma, act by blocking the ability of KIF1Bβ to 
initiate apoptosis. Although earlier studies had placed KIF1Bβ in the shortest regions of 
overlap found in 1p36 deletions in neuroblastoma (Bauer et al., 2001; White et al., 2005), 
these mechanistic insights into the molecular function of KIF1Bβ along with the 
identification of cancer-associated missense mutations provided the first real evidence that 
KIF1Bβ might be a haplo-insufficient neuroblastoma tumour suppressor on chromosome 
1p36. Additional work showed that, of the potential 1p36 tumour suppressor genes, KIF1Bβ 
was the only one that suppressed growth of neuroblastoma cell cultures and xenografted 
tumours (Munirajan et al., 2008). Significantly, these studies by Munirajan and colleagues 
narrowed down the part of the KIF1Bβ protein required for it to induce apoptosis. These 
results suggested that KIF1Bβ’s ability to transport molecular cargoes is not required for 
apoptosis, as functionally deleterious mutations in the KIF1Bβ motor domain and fork-head 
associated domain did not block apoptosis (Munirajan et al., 2008).  
These studies argue that KIF1Bβ is a putative neuroblastoma tumour suppressor on 1p36, 
implying that defective culling of sympathetic neurons during development may contribute to 
neuroblastoma oncogenesis. Further studies are clearly required to investigate 
mechanistically how KIF1Bβ regulates apoptosis, and the implications of deregulated 
sympathetic neuron culling for neuroblastoma pathogenesis in vivo. Future work should also 
reveal if and how the remaining wild-type allele of KIF1Bβ is silenced in neuroblastoma as 
the aforementioned studies indicate that the KIF1Bβ promoter is not silenced by DNA hyper-
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methylation in 1p36 +/- tumours and that complete ablation of KIF1Bβ expression kills 
neurons (Munirajan et al., 2008; Schlisio et al., 2008) 
 
1.12 KIF1BΒ, A MOLECULAR MOTOR PROTEIN  
 
KIF1Bβ is a group 3 kinesin (Lawrence et al., 2004), and is one of several protein isoforms 
expressed from the KIF1B gene.  Kinesins are motor proteins that transport molecular 
cargoes along microtubules. KIF1Bβ contains three recognised functionally conserved 
domains; an N-terminal motor ATPase domain that drives ATP- dependent movement along 
microtubules, a forkhead associated (FHA) domain, that may facilitate interaction with 
phospho-proteins and a pleckstrin homology (PH) domain that mediates binding to 
phosphoinositide rich membranes (Hirokawa et al., 2009; Klopfenstein et al., 2002). Between 
the FHA domain and the PH domain is a unique region that appears to mediate interaction 
with cargoes and other adaptor proteins (Figure 2). In contrast to other kinesins, the KIF1B 
proteins are functional monomers and have an unusually compact, globular tertiary structure 
compared to the typical kinesin architecture with the motor domain anchored to the 
microtubule and the c-terminal tail sticking up like a stalk (Hirokawa et al., 2009; Nangaku et 
al., 1994). 
 
Group 3 kinesins, such as KIF1Bβ traffic their cargoes towards the microtubules’ plus end, 
which generally entails movement from the centre of the cell out towards the periphery and 
cell membrane. Previous studies have demonstrated that KIF1Bβ transports mRNAs in 
neurons (Charalambous et al., 2013) and synaptic vesicles (Zhao et al., 2001). This transport 
activity appears to depend upon interactions with proteins such as RAB3A and the adaptor 
proteins KIF1BP and MADD (Drerup et al., 2016; Niwa et al., 2008). Interactions with 
specific lipids, such as PtdIns(4,5)P2, also appear to be crucial for regulating interactions with 
vesicular membranes (Klopfenstein et al., 2002). These studies indicate that KIF1Bβ is 
required for the transport of several specific cargoes, yet KIF1Bβ most likely transports more, 
as yet undiscovered, molecules or intracellular objects. Future work should reveal these new 
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Figure 2: Diagram of KIF1Bbeta protein including functionally conserved domains 
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cargoes, and the molecular interactions and adaptor proteins that determine specify of binding 
to, and transport by KIF1Bβ. 
Earlier investigations have also suggested a role for KIF1Bβ in axon development and 
maintenance in zebrafish (Lyons et al., 2009; Pogoda et al., 2006). Talbot and colleagues 
demonstrated that a loss of function mutation in the motor domain of KIF1Bβ causes defects 
in axon development and myelination that mirror those seen in multiple sclerosis. Another 
mutation in the KIF1Bβ motor domain was also recently associated with amyotrophic lateral 
sclerosis (Herdewyn et al., 2012). Mutations in the KIF1B gene are also associated with 
Charcot-Marie-Tooth disease (CMT), a fairly common, hereditary neurological disorder. 
Pertinently, a specific loss-of-function mutation in the KIF1Bb motor domain carried by a 
Japanese CMT family was shown to impair axonal protein transport and cause peripheral 
neuropathy in mice (Zhao et al., 2001). Furthermore, a recent study has implicated KIF1Bβ in 
the transport of STMN2, a key protein for axon growth in the peripheral nervous system. 
From these studies it is clear that KIF1Bβ plays an important role in neuronal development 
and maintenance. However, in vivo studies of KIF1Bβ function and tumour suppressor 
activity have been hindered by the perinatal death of mice with homozygous loss of KIF1Bβ 
due to nervous system defects (Zhao et al., 2001). 
 
1.13 SUMMARY 
 
The low number of protein effecting mutations found in childhood cancers suggests that they 
might originate from cells particularly susceptible to transformation. The many stem cells, 
expanding cell populations, and growth promoting environmental niches present during 
embryonic development appear to provide favourable conditions for cancer development, and 
it seems likely that many paediatric malignancies begin in the embryo. Neuroblastoma is a 
childhood cancer that appears to arise from sporadic defects during embryogenesis. Failure of 
either cell differentiation or culling of undifferentiated cells during embryogenesis are 
processes that could lead to an abnormal accumulation of undesired cells that have, or are 
predisposed to obtain, cancerous properties. There is considerable evidence that such 
embryonic ‘pre-cancers’ commonly arise in the sympathetic nervous system, and can precede 
neuroblastoma. KIF1Bβ is a putative neuroblastoma tumour suppressor protein that is 
required for apoptosis of sympathetic neurons deprived of NGF. The molecular mechanisms 
by which KIF1Bβ regulates apoptosis are as yet unknown. Neither has the function and 
importance of KIF1Bβ in sympathoadrenal development and tumour-suppression been 
investigated in vivo.  
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2 AIMS 
 
 
In Paper I we aimed to discover how, mechanistically, KIF1Bβ regulates neuronal apoptosis. 
 
In Paper II, we continued to explore the molecular function of KIF1Bβ in apoptosis-
induction and neuroblastoma tumour suppression.  Specifically, the work in this paper 
explores a finding made during work on Paper I, that KIF1Bβ physically interacts with 
CALM2, a protein involved in intracellular calcium dependent signalling that is critical for a 
myriad of neuronal functions.  
 
Paper III presents an investigation of the in vivo function of KIF1Bβ in the sympathetic 
nervous system using a conditional knock out mouse model. 
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3 RESULTS AND DISCUSSION 
 
3.1 PAPER I 
 
In this paper we investigated the molecular mechanisms behind KIF1Bβ’s involvement in 
cell death and putative neuroblastoma tumour suppression.  We confirmed that the minimal 
region of KIF1Bβ capable of inducing apoptosis was  located between the FHA and PH 
domains as previously published (Munirajan et al., 2008) and narrowed down this region 
further (minimal apoptotic domain - amino acid residues 1000-1400 in human KIF1Bβ), 
clearly demonstrating that the apoptotic activity of KIF1Bβ is independent of its motor 
activity. 
Using immunoprecipitation experiments coupled with mass spectrometry, we discovered that 
KIF1Bβ interacts with an RNA helicase, DHX9, and that DHX9 binds to the minimal 
apoptotic domain of KIF1Bβ. DHX9 regulates gene expression through its effects on local 
chromatin structure and function in transcriptional activation, RNA splicing and translation 
(Fuller-Pace, 2006). We show that KIF1Bβ promotes translocation of DHX9 into the nucleus 
of neuroblastoma cells, and that the DHX9 transcriptional activation domain is needed in 
order for KIF1Bβ to induce apoptosis. Subsequent RNA-seq transcriptome analysis revealed 
that KIF1Bβ overexpression stimulates a DHX9-dependent transcriptional response that 
features upregulation of pro-apoptotic proteins, such as XAF1. Importantly, loss of DHX9 
expression protects cells from NGF-deprivation induced apoptosis. The nuclear localisation 
of DHX9, and implicitly it’s transcriptional activity, depends upon KIF1Bβ expression in 
primary human neuroblastoma tumours and in the sympathetic ganglia of mice. 
The discovery that DHX9 acts downstream of KIF1Bβ during NGF-deprivation induced 
apoptosis accords with early reports showing that gene transcription and translation are 
required for this mode of cell death in sympathetic neurons (Edwards and Tolkovsky, 1994; 
Martin, 1988). While at first glance the importance of an RNA helicase for a transcription and 
translation dependent process may seem self-evident, other studies are emerging that describe 
specific DHX9 mutations and RNA helicase disruption in other cancer settings such as breast 
cancer and medulloblastoma (Fidaleo et al., 2016; Guénard et al., 2009), suggesting that 
DHX9 may have tumour-suppressive and oncogenic functions depending on physiological 
context.  
Although we demonstrated that DHX9 is required for apoptosis induced by ectopically 
expressed KIF1Bβ and that KIF1Bβ is required for DHX9 nuclear translocation, our 
experiments indicated that DHX9 also regulates the expression of endogenous KIF1Bβ. We 
did not investigate this in depth in this paper. However, we speculate that DHX9 may exert a 
post-transcriptional influence on KIF1Bβ expression from outside the nucleus. Insights into 
the molecular mechanisms controlling KIF1Bβ expression might prove valuable for 
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understanding neuroblastoma pathogenesis.  Loss of the 1p36 locus usually occurs 
hemizygously in neuroblastoma (Maris et al., 2000), but we (in Paper I, see also paper II) and 
others (Munirajan et al., 2008) observe that KIF1Bβ protein is most often absent from 1p36 
+/- tumours. Hypermethylation of the promoter site does not seem to account for silencing of 
KIF1Bβ expression on the remaining wild-type allele (Munirajan et al., 2008), and our own 
unpublished data examining hemizygous loss of 1p36 in pheochromocytoma demonstrate no 
reduction in KIF1Bβ mRNA in 1p36 +/- tumours, relative to 1p36+/+ tumours or normal 
adrenal tissue. Similarly, silencing of another putative 1p36 tumour suppressor gene, CHD5, 
does not depend on promoter hypermethylation in 1p36 +/- neuroblastoma (Koyama et al., 
2012). These findings imply that silencing of the remnant wild-type allele in 1p36+/- tumours 
most likely occurs via post transcriptional regulation of gene expression. Investigation of the 
biological mechanism behind this is warranted, as experimental data suggests that alleviating 
loss-of-heterozygosity at 1p36 could suppress neuroblastoma and enhance therapeutic 
success (Bader et al., 1991). Furthermore, many of the post-transcriptional regulatory 
enzymes may present attractive targets for future chemotherapeutics that are both targetable 
with small molecules and associated with cancer-specific gene expression programs. 
Curiously, we showed that some NB-associated KIF1Bβ mutants have a reduced ability to 
affect DHX9 translocation to the nucleus. Those mutants that acted unimpaired on DHX9, 
were still unable to induce apoptosis (Paper I, Schlisio et al., 2008), implying that additional 
mechanisms lie behind KIF1Bβ’s apoptotic function. Subsequent investigation of these 
mechanisms is presented in Paper II.  
 
3.2 PAPER II 
 
In this paper we continued our exploration of the molecular mechanism responsible for 
KIF1Bβ induced apoptosis. Here, we pursued a preliminary finding made in the process of 
work on Paper I, that KIF1Bβ interacts with CALM2, a calcium-binding protein involved in 
various calcium-sensitive signalling pathways. Interaction between KIF1Bβ and CALM2 was 
suggested by a previous study (Charalambous et al., 2013), but the functional implications of 
the interaction were not explored. We demonstrated that KIF1Bβ stabilises the binding of 
CALM2 to Calcineurin (CN), a serine/threonine protein phosphatase complex, and facilitates 
CN phosphatase activity. We found that KIF1Bβ is required for CN-mediated 
dephosphorylation of serine-637 on the mitochondrial fission protein DRP1, inducing 
translocation of DRP1 to the mitochondria, mitochondrial fission and apoptosis. Furthermore, 
DRP1, CALM2 and CNA (PPP3CA), the enzymatic subunit of the CN complex, are required 
for KIF1Bβ to initiate apoptosis, and for apoptosis of sympathetic neurons deprived of NGF. 
Previous studies have shown that DRP1 is required for developmentally regulated apoptosis 
during neural tube formation (Wakabayashi et al., 2009). 
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In Paper I we found that neuroblastoma tumours with intact chromosome 1p36 express 
KIF1Bβ protein, in contrast to 1p36 hemizygous deleted tumours that lack KIF1Bβ. Here we 
extended this observation using a larger set of neuroblastomas. The absence of KIF1Bβ in the 
1p36+/- tumours implies that KIF1Bβ might be a pathogenic target of 1p36 loss in 
neuroblastoma and we showed that indeed low expression of KIF1Bβ  is correlated with 
worse prognosis and more advanced disease. Likewise, neuroblastoma tumours with low 
expression of DRP1 have worse patient outcome and more advanced stage, indicating that 
DRP1 may also have tumour suppressive properties in neuroblastoma. Curiously, DRP1 
protein was largely absent from 1p36 +/- tumours. In neuroblastoma cell lines we only 
observed KIF1Bβ dependent changes in DRP1 phosphorylation, rather than expression. The 
loss of both of these proteins from 1p36+/- tumours suggests that they are not functionally 
redundant and that they most likely have other functions that effect neuroblastoma 
pathogenesis that were not explored in this study.  
However, it should be noted that other studies have reported additional functions of DRP1 
that could be relevant in neuroblastoma. DRP1 is a member of the dynamin family of proteins 
that execute GTP-dependent fission of membranous structures. Previous studies have shown 
that DRP1 is involved in various fission activities, including endosomal cleavage from the 
plasma membrane, peroxisome fission and regulation of the endoplasmic reticulum, in 
addition to mitochondrial fission (Koch et al., 2003; Li et al., 2013; Pitts et al., 1999; 
Smirnova et al., 2001). It is highly conceivable that disruption of these other DRP1 functions 
could have a role in neuroblastoma oncogenesis. In particular, perturbed mitochondrial and 
peroxisomal dynamics due to loss of DRP1 have also been reported to cause neuronal 
degeneration through impaired mitochondrial function linked to reactive oxygen species 
(Chen, 2005; Cho et al., 2009; Wang et al., 2009). Increased ROS and derailed mitochondrial 
energy metabolism are typical features of cancer cells, so it is also possible that silencing of 
DRP1 could contribute to neuroblastoma development through such effects.  
The molecular motor dependent activity of KIF1Bβ may also figure in neuroblastoma tumour 
suppression. The interaction that we document between KIF1Bβ and the CN-CALM2 
complex in Paper II does not depend on KIF1Bβ motor function. However, DRP1-
independent activities of KIF1Bβ could also complement tumour-suppressive DRP1 
dependent activity. In this regard, KIF1Bβ cargo transport activity in developing sympathetic 
neuroblasts is investigated in Paper III.  
The work presented in Paper II answered a lingering question posed in Paper I – How does 
KIF1Bβ affect DHX9 nuclear translocation, and activity during neuronal apoptosis? In Paper 
II we found that human DHX9 has a CN recognition motif (LxVP) from amino acid residue 
647 to 650. Our subsequent experiments demonstrated that in the presence of KIF1Bβ in 
vitro, CN could dephosphorylate a DHX9 peptide that contained this sequence. We then 
showed that CNA is required for KIF1Bβ mediated, nuclear translocation of DHX9 in 
neuroblastoma cell lines, implying that CN enzymatic activity was the mechanistic missing 
link between DHX9 and KIF1Bβ in Paper I. 
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The most unexpected finding in Paper II is that KIF1Bβ acts as a critical adaptor protein for 
the activity of the CN enzymatic complex. We found that KIF1Bβ acts as a scaffold for the 
CN-CALM2 complex, binding to both CNA and CALM2 (but not CNB) and potentiating CN 
enzymatic activity. CN is composed of an enzymatic subunit, CNA, and a regulatory subunit, 
CNB. CALM2 binding to CN in the presence of Ca2+  prompts a conformational change in 
CN, which shifts an auto-inhibitory structural loop in the CNA protein and opens up the 
enzymatic active site for substrate binding (Li et al., 2011). Our experimental data indicate 
that KIF1Bβ is required for full calcineurin enzymatic activity because it stabilises the 
interaction between CN and CALM2, and is required for CN phosphatase activity on a 
variety of substrates in vitro.  We therefore speculated that KIF1Bβ acts as an allosteric 
regulator of CN activity by relieving enzymatic auto-inhibition.  
This hypothesis departs from the prevailing model of calcineurin activity, whereby CALM2 
binding to CN in the presence of calcium is sufficient for enzymatic activation (Li et al., 
2011; Wang et al., 2008). Our results indicate that while the CN-CALM2 complex is partially 
active in optimised in vitro conditions, the binding of an adaptor protein such as KIF1Bβ can 
massively increase CN phosphatase activity. In this paper we demonstrated that this is critical 
for apoptosis induced by ectopic KIF1Bβ expression and NGF-deprivation in sympathetic 
neurons.  
Surprisingly for us, we also observed that KIF1Bβ was required for dephosphorylation of all 
the other known calcineurin substrates that we tested in vitro. Calcineurin regulates a broad 
range of cellular signalling pathways, promoting diverse cell biological responses (Li et al., 
2011). We have observed KIF1Bβ expression in the brain and nervous system, and other 
neural crest derived tissues, and it is also expressed at lower levels in various other tissues 
including skeletal muscle, blood and in the testis (Lonsdale et al., 2013). It appears unlikely 
that KIF1Bβ regulates the full range of CN activities in all these tissues in vivo. Interaction 
between KIF1Bβ and calcineurin is potentially constrained somewhat by intracellular 
segregation of these proteins in different subcellular compartments or areas. Intriguingly, our 
findings open the door for discovery of novel CN adaptor proteins that regulate CN signalling 
in other physiological and pathological contexts. CN signalling is de-regulated in many 
diseases. Our findings in Paper II indicate that the design of synthetic adaptor peptides could 
potentially be used to modulate CN activity in a therapeutic context.  
 
3.3 PAPER III 
 
To investigate the role of KIF1Bβ in vivo in sympathoadrenal development and potential 
neuroblastoma tumour suppression we created mice with a conditional deletion of KIF1Bβ 
driven by expression of the noradrenergic gene DBH (KIF1Bβ cKO mice). KIF1Bβ 
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expression is ablated in the sympathetic neuroblasts of these mice. Based on the results 
observed in Papers I and II, and previous studies, we expected that these mice would develop 
a hyperplasia in the developing sympathetic nervous system due to defective developmental 
culling of sympathetic neurons. 
Contrary to our expectations, KIF1Bβ cKO mice have smaller sympathetic ganglia than their 
wild-type littermates. In Paper III, we show that loss of KIF1Bβ causes developmental loss of 
sympathetic neurons, leading to impaired target innervation and sympathetic nervous system 
function. We describe misexpression of critical markers of sympathetic identity in KIF1Bβ 
cKO neurons from the superior cervical ganglia (SCG). Investigating this, we revealed that 
KIF1Bβ enables NGF induced neuronal differentiation by anterograde trafficking of the NGF 
receptor, TRKA.  
A recent study argues that KIF1A is the main kinesin responsible for anterograde transport of 
TRKA in sensory neurons of the adult dorsal root ganglia (DRG) and that heterozygous loss 
of KIF1A leads to sensory neuropathy (Tanaka et al., 2016). Tanaka et al. argue that KIF1A 
is predominantly expressed in adult DRG, while KIF1Bβ is more highly expressed during 
embryonic development and in regenerating neurons. Furthermore, immunoprecipitation 
experiments are presented that suggest TRKA binds to KIF1A in the adult brain, but not to 
KIF1Bβ. In contrast, we found that TRKA binds to KIF1Bβ in sympathetic neurons and 
neuroblastoma cell lines, but did not observe any association between KIF1A and TRKA in 
our experiments despite the abundance of both kinesins. We also observed persistent 
expression of KIF1Bβ in adult sympathetic neurons, and, somewhat curiously, Tanaka and 
colleagues also observe KIF1Bβ protein in adult brain. Interestingly, the same authors 
published an earlier study demonstrating that heterozygous loss of KIF1B, and implicitly 
KIF1Bβ, causes peripheral neuropathy. This casts some doubt on the developmentally 
segregated expression and function of these proteins proposed by Tanaka and co. While there 
are inconsistencies between Paper III and the work presented by Tanaka et al., we 
demonstrate that, at least in cells of sympathoadrenal origin, KIF1Bβ is the main kinesin 
responsible for anterograde transport of TRKA. 
We showed that the loss of sympathetic neurons in KIF1Bβ cKO mice occurs due to 
abnormal death of neuronal progenitors during embryogenesis. KIF1Bβ cKO neurons have a 
reduced capacity to survive when cultured with low concentrations of NGF and display an 
attenuated NGF neurotrophic signal manifest as reduced phosphorylation of ERK1/2.  In 
agreement with these observations, complete, acute knockdown of KIF1Bβ was previously 
reported to cause cell death in sympathetic neuron cultures (Schlisio et al., 2008). We 
hypothesised that loss of KIF1Bβ blocks NGF-TRKA neurotrophic signalling, leading to cell 
death, and that this could be avoided by introduction of an artificial ERK-mediated survival 
signal. To this end, we combined conditional knockout of KIF1Bβ with conditional knockout 
of NF1. NF1 is a RAS-GAP protein that modulates the downstream signal of several groups 
of trophic factor receptors, including TRKA.  We showed that loss of NF1 restored the 
reduced size and the impaired ERK1/2 phsophorylation in KIF1Bβ cKO sympathetic ganglia, 
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supporting our hypothesis. Although further experiments are required to verify that loss of 
NF1 actually ameliorates the elevated apoptosis in KIF1Bβ cKO neurons, or whether the 
increased size of NF1; KIF1Bβ double cKO ganglia is simply due to increased neuroblast 
proliferation. 
In paper II we demonstrated that KIF1Bβ is required for full activation of calcineurin, CN.  
CN regulates many calcium sensitive signalling pathways and is important for neuronal 
development and activity (Graef et al., 2003; Yakel, 1997). In Paper III we found that CN 
was not required for NGF-mediated neuronal differentiation of neuroblastoma cells or 
pheochromocytoma cells, implying that the pro-apoptotic motor-independent functions of 
KIF1Bβ, are likely distinct from KIF1Bβ’s motor dependent, TRKA transport activity. It is 
difficult to dissect these two functions in vivo with a knockout mouse, due to the two-sided 
nature of TRKA. i.e. neurons that lack TRKA will die due to lack of NGF neurotrophic 
signal, however neurons that express TRKA, but do not receive NGF will also die due to an 
incompletely understood, but TRKA dependent pro-apoptotic mechanism (Nikoletopoulou et 
al., 2010). Consequently, KIF1Bβ-deficient sympathetic ganglia are already reduced in size, 
due to neuronal apoptosis, before normal NGF-dependent developmental culling of excess 
sympathetic progenitors has begun. One approach that could be used to distinguish the 
apparently separate KIF1Bβ functions in sympathetic neuron development would be to add 
back a motor-deficient mutant KIF1Bβ into KIF1Bβ knockout mice, or to introduce the 
corresponding specific amino acid substitution into the KIF1B locus of wild type mice using 
gene-editing technology (Wang et al., 2013).  
In Paper III we compared gene expression profiles from KIF1Bβ cKO SCGs with gene 
expression data from large sets of neuroblastoma tumours. We employed this method to 
model what the specific effects of KIF1Bβ loss might be in neuroblastoma, since KIF1Bβ is 
commonly lost along with contiguous genes on 1p36 making it hard to distinguish individual 
gene specific effects of 1p36 loss in neuroblastoma. This is further complicated by the 
common co-occurrence of 1p36 loss with MYCN amplification, that has a strong influence 
over neuroblastoma character and prognosis in its own right. We found that clustering non-
MYCN amplified neuroblastoma tumours according to genes differentially expressed in 
KIF1Bβ cKO SCGs produced prognostically relevant groupings. Specifically, clustering 
tumours based on their expression of genes down regulated in KIF1Bβ cKO SCGs, gave two 
clear groups of tumours. The group of tumours that had lower expression of the genes 
downregulated in KIF1Bβ cKO SCGs, i.e. those tumours that most resembled KIF1Bβ cKO 
neurons, had worse patient outcome and were associated with high-risk disease and advanced 
INSS disease stage. Tellingly, the most depleted and enriched genesets in this group of 
tumours were highly similar to those correlated with KIF1Bβ expression in neuroblastoma 
and those identified in KIF1Bβ cKO SCGs. This comparative analysis of gene expression 
implies that loss of KIF1Bβ contributes to neuroblastoma pathogenesis, independent of 
contiguous genes on 1p36 and MYCN-amplification. 
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Expression of the NGF receptor TRKA is a strong prognostic factor in MYCN non-amplified 
neuroblastoma. Furthermore, hemizygous loss of chromosomal locus 1p36 is strongly 
correlated with poor prognosis. Our finding that the 1p36 candidate tumor suppressor 
KIF1Bβ is required for NGF mediated neuroblast differentiation by mediating the 
anterograde transport of TRKA, provides a potential molecular explanation for the reduced 
expression of neuronal differentiation markers in 1p36+/- neuroblastomas and associated 
poor prognosis. 
At present, the only mouse models of neuroblastoma are the TH-MYCN mouse (Weiss et al., 
1997) and the mice lines over-expressing mutant ALK developed by Johannes Schulte and 
colleagues (Heukamp et al., 2012).  These tumour models are based on miss-expression of an 
oncogene driven by the promoter region of either of the noradrenergic genes TH or DBH. No 
mouse models of neuroblastoma involving deletion of a tumour suppressor gene have been 
reported to date. We hypothesised that our KIF1Bβ cKO mice would develop hyperplastic 
sympathetic ganglia due to impaired developmental culling, and that these mice might also 
have developed neuroblastoma. However, the phenotype observed in our KIF1Bβ cKO mice 
diverged from our expectations. This might be due in part to the developmental timing of the 
knockout and the need for a collaborating oncogenic event. For example, conditional 
knockout of CREB, a transcription factor required for NGF-dependent sympathetic neuron 
survival in vitro (Riccio et al., 1999), driven by the DBH promoter increased sympathetic 
neuronal survival during developmental culling (Parlato et al., 2007). However, germ line 
ablation of CREB reduced sympathetic neuroblast survival and migration before the 
acquisition of NGF-dependence. This effect resembled that caused by loss of RET and 
GFRA3 during neuroblast migration and proliferation (Enomoto et al., 2001; Nishino et al., 
1999), and suggested a role for CREB in RET signalling, in addition to its later 
developmental function in NGF signalling (Parlato et al., 2007). The phenotypic effect of the 
CREB knockout on sympathetic neurons is determined by developmental timing of the 
knockout.   
Similarly, earlier ablation of KIF1Bβ may affect sympathetic neuroblasts differently to the 
DBH driven knockout of KIF1Bβ used in Paper III and reveal novel KIF1Bβ functions. In 
particular, future investigations of the role of KIF1Bβ, and other potential neuroblastoma 
tumour suppressors may benefit from earlier conditional knockouts. The DBH and TH 
promoters drive transgene expression in sympathetic neuroblasts from around embryonic day 
11. This means that transgenes, such as TH-MYCN, are expressed from around E11 when 
neuroblasts commence a short period of proliferation from about E11-E15, and are likely 
most susceptible to oncogenic stimuli. In contrast, TH or DBH driven gene ablation, as used 
in Paper III, might not remove the protein in question until E13.5 (Paper III, Parlato et al., 
2007) when the majority of neuroblast proliferation and, with it, potential sensitivity to 
oncogenic disruption has passed. Future in vivo studies using different transgenic approaches 
are required and will undoubtedly reveal more about neuroblastoma tumour suppression by 
KIF1Bβ and other putative 1p36 tumour suppressors. 
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